Single Dose of Recombinant Chimeric Horsepox Virus (TNX-801) Vaccination Protects Macaques from Lethal Monkeypox Challenge
The ongoing global Monkeypox outbreak that started in the spring of 2022 has reinforced the importance of protecting the population using live virus vaccines based on the vaccinia virus (VACV). Smallpox also remains a biothreat and although some U.S. military personnel are immunized with VACV, safety concerns limit its use in other vulnerable groups. Consequently, there is a need for an effective and safer, single dose, live replicating vaccine against both viruses. One potential approach is to use the horsepox virus (HPXV) as a vaccine. Contemporary VACV shares a common ancestor with HPXV, which from the time of Edward Jenner and through the 19th century, was extensively used to vaccinate against smallpox. However, it is unknown if early HPXV-based vaccines exhibited different safety and efficacy profiles compared to modern VACV. A deeper understanding of HPXV as a vaccine platform may allow the construction of safer and more effective vaccines against the poxvirus family. In a proof-of-concept study, we vaccinated cynomolgus macaques with TNX-801, a recombinant chimeric horsepox virus (rcHPXV), and showed that the vaccine elicited protective immune responses against a lethal challenge with monkeypox virus (MPXV), strain Zaire. The vaccine was well tolerated and protected animals from the development of lesions and severe disease. These encouraging data support the further development of TNX-801.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Viruses - 15(2023), 2 vom: 26. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Noyce, Ryan S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Horsepox |
|---|
| Anmerkungen: |
Date Completed 01.03.2023 Date Revised 13.12.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/v15020356 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353576530 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353576530 | ||
| 003 | DE-627 | ||
| 005 | 20231227131135.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/v15020356 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM353576530 | ||
| 035 | |a (NLM)36851570 | ||
| 035 | |a (PII)356 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Noyce, Ryan S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Single Dose of Recombinant Chimeric Horsepox Virus (TNX-801) Vaccination Protects Macaques from Lethal Monkeypox Challenge |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.03.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The ongoing global Monkeypox outbreak that started in the spring of 2022 has reinforced the importance of protecting the population using live virus vaccines based on the vaccinia virus (VACV). Smallpox also remains a biothreat and although some U.S. military personnel are immunized with VACV, safety concerns limit its use in other vulnerable groups. Consequently, there is a need for an effective and safer, single dose, live replicating vaccine against both viruses. One potential approach is to use the horsepox virus (HPXV) as a vaccine. Contemporary VACV shares a common ancestor with HPXV, which from the time of Edward Jenner and through the 19th century, was extensively used to vaccinate against smallpox. However, it is unknown if early HPXV-based vaccines exhibited different safety and efficacy profiles compared to modern VACV. A deeper understanding of HPXV as a vaccine platform may allow the construction of safer and more effective vaccines against the poxvirus family. In a proof-of-concept study, we vaccinated cynomolgus macaques with TNX-801, a recombinant chimeric horsepox virus (rcHPXV), and showed that the vaccine elicited protective immune responses against a lethal challenge with monkeypox virus (MPXV), strain Zaire. The vaccine was well tolerated and protected animals from the development of lesions and severe disease. These encouraging data support the further development of TNX-801 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a horsepox | |
| 650 | 4 | |a immune responses | |
| 650 | 4 | |a monkeypox | |
| 650 | 4 | |a smallpox | |
| 650 | 4 | |a vaccinia | |
| 650 | 7 | |a Vaccines, Attenuated |2 NLM | |
| 700 | 1 | |a Westfall, Landon W |e verfasserin |4 aut | |
| 700 | 1 | |a Fogarty, Siobhan |e verfasserin |4 aut | |
| 700 | 1 | |a Gilbert, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Mpanju, Onesmo |e verfasserin |4 aut | |
| 700 | 1 | |a Stillwell, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Esparza, José |e verfasserin |4 aut | |
| 700 | 1 | |a Daugherty, Bruce |e verfasserin |4 aut | |
| 700 | 1 | |a Koide, Fusataka |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, David H |e verfasserin |4 aut | |
| 700 | 1 | |a Lederman, Seth |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Viruses |d 2009 |g 15(2023), 2 vom: 26. Jan. |w (DE-627)NLM192382764 |x 1999-4915 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:2 |g day:26 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/v15020356 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 2 |b 26 |c 01 | ||